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ABSTRACT
Venom Peptides Lasioglossin II and Mastoparan B as
Escherichia coli ATP synthase Inhibitors
by
Rafiat Bello
The inhibitory effects on Escherichia coli ATPase activity by two venom peptides, lasioglossin
II and mastoparan B. Membrane bound F1FO ATP synthase was isolated from E. coli strain
pBWU13.4/DK8 and treated with varied concentrations of lasioglossin II and mastoparan B.
Lasioglossin II caused very low inhibition of ATPase activity, but the inhibition profile of
mastoparan B was suggestive of an interesting biological effect. A relatively shorter total length,
a smaller net positive charge, and a reduced amphipathic character of both peptides, as compared
to previously tested antimicrobial peptides, may account for the limited degree of inhibition
observed in the present study.
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CHAPTER 1
INTRODUCTION
Several natural and synthetic compounds have been described as inhibitors of ATP
synthase. One such group of inhibitors are Antimicrobial Peptides (AMPs). Several possible
mechanisms have been described regarding the activity of AMPs. The most accepted models are
membrane permeabilization and cell death (apoptosis) by either toroidal pore model, barrel stave
model, or carpet model. Mechanism of activity studies suggest that AMPs seem to connect with
negatively charged, anionic phospholipid layers thereby injecting itself into the bacterial cell
membrane. AMPs can also extend over the cell membrane by passive transport upsetting some of
the cellular activities in there. Dermaseptins seem to induce a non-pore dependent cytolytic
process that results in breakdown and miscellization of the membrane bilayer (Shai 2002). A
previously examined hypothesis concerning the antimicrobial effects of AMPs is based on their
possible inhibitory effects on ATP synthase. This hypothesis was motivated by the observation
that several other peptides which conform to basic amphiphilic α-helical structures are reported
to bind at the βDELSEED-loop of E. coli ATP synthase (Ahmad et al. 2015).
Ahmad and Laughlin (2010) discussed the concept that amphibian AMPs with possible
inhibitory effects on ATP synthase, through binding at the βDELSEED-loop, would be relatively
short positively charged peptides of ~10-30 amino acid residues, with α-helical secondary
structure, and has antibacterial or anticancer effects. Previous studies suggested that in a state of
low adenosine-5‘-triphosphate (ATP) and high H+ gradients concentrations, the C-terminal αhelical domain of the ε-subunit of F1-ATPase experience enormous structural changes then join
with the α3β3 hexagon ring, where it is places in the vicinity of the βDELSEED-loop (Ahmad et
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al. 2015). Electrostatic interactions between basic residues of the ε-subunit and the acidic
residues of βDELSEED-motif result in inhibition of ATPase activity (Hara et al. 2001b; Tsunoda
et al. 2001; Suzuki et al. 2003). Inhibition of ATP synthase has been demonstrated to defend or
delay cell damage by conserving ATP during ischaemia (Vuorinen et al. 1995). Because short
linear cationic α-helical peptides with antimicrobial activity would be fascinating candidates as
therapeutic agents, I examined the venom peptides mastoparan B and lasioglossin II as possible
inhibitors of Escherichia coli ATP synthase.

Hypothesis
Venom peptides Mastoparan B and lasioglossin II can inhibit Escherichia coli ATP
synthase activity.

ATP synthase is a ubiquitous multi-subunit membrane enzyme that participate and plays
a major role in cellular energy production. This membrane bound enzyme is found in almost
every living cell. ATP synthase is highly conserved and structurally homologous in all
organisms. In prokaryotes, ATP synthase is embedded in the plasma membrane, but it is located
in the thylakoid membrane of chloroplasts of higher plants, and in the inner membrane of
mitochondria in eukaryotic cells. ATP synthase is also spot on the exterior of various
mammalian cell kinds, including endothelial cells, adipocytes, and keratinocytes (Hong and
Pedersen 2008). ATP synthase is the terminal enzyme in the oxidative phosphorylation pathway.
It activates ATP synthesis by oxidative phosphorylation or by photophosphorylation in the
membranes of cells and organelles (Ahmad and Laughlin 2010). ATP synthase utilizes energy
from a proton motive force generated by the electron transport chain to catalyze the production
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of adenosine-5‘-triphosphate (ATP) from adenosine-5‘-diphosphate (ADP) and inorganic
phosphate (Pi). In some bacteria, ATP synthase reverses this activity by functioning as an ATPdriven proton pump that generates a proton (H+) gradient. The energy available from ATP is
used for a number of cellular processes, including active transport of molecules across cell
membranes, transport of nutrients, motility, nucleic acid synthesis, and protein synthesis.

Inhibitors of ATP Synthase
The inhibitory eﬀects on ATP synthase, and the range of inhibition are fluctuating on a
molar scale among various inhibitors. Inhibitors can be classified based on bond formation
(Gledhill and Walker 2006) and other physical and chemical properties (Hong and Pedersen
2008).
Based on bond formation with ATP synthase, they are grouped into two types.
1. The covalent inhibitors include 4-chloro-7-nitrobenzofurazan (NBD-Cl), N,N΄dicyclohexylcarbodiimide (DCCD), 8-azido-ATP, 2-azido-ATP, 5΄-p-fluorosulphonylbenzoyladenosine and 5΄-p-fluorosulphonylbenzoylinosine.
2. The non-covalent inhibitors include natural inhibitor protein IF1, amphiphilic peptides,
non-peptidyl lipophilic cations, polyphenolic phytochemicals, non-hydrolysable substrate
analogues, aurovertins and efrapeptins.
Based on other physical and chemical properties of inhibitors, they are grouped into nine
types.
1. Peptide inhibitors include:
•

α-Helical basic peptide inhibitors: include the natural inhibitor protein IF1,
bacterial/chloroplast ε subunit, antimicrobial peptides (AMP) like melittin,
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dermaseptin, maculatin, aurein and venom peptides such as mastoparan B and
lasioglossin II
•

Angiostatin and enterostatin

•

Leucinostatins and efrapeptins

•

Tentoxin and its derivatives

Efrapeptin is an effective strong inhibitor of soluble ATP synthase compared to other
compounds known to inhibit this enzyme like aurovertin and citreoviridin, efrapeptin is capable
of causing maximium inhibition (Jackson et al. 1979). The binding site for the F1 targeting
inhibitor efrapeptin is found in α, β and γ subunits (Abrahams et al. 1996) while that of
aurovertin B is primarily confined to the β subunit (van Raajj et al. 1996).
2. Polyphenolic phytochemicals, estrogens and structurally related compounds include:
•

Flavones and isoflavones: including quercetin, kaempfero, thymoquinone, morin
apigenin, genistein, biochanin A and daidzein.

•

Stilbenes: including resveratrol, piceatannol, diethylstilbestrol (DES),
diisothiocyanatostilbene- 2,2-disulfonic acid (DIDS) and 4-acetamido-4isothiocyanostilbene 2,2 -disulfonate (SITS).

•

Steroidal estradiols and estrogen metabolites: including 4-hydroxyestradiol, 2hydroxyestradiol, 17-α-estradiol, 17-β-estradiol α-zearalenol and β-zearalenol.

•

Other polyphenolic phytochemicals: including epicatechin gallate (ECG),
epigallocatechin gallate (EGCG), curcumin, phloretin, theaflavin and tannic acid.

Oestradiol and several other oestrogens have been shown to inhibit the activity of rat brain
FOF1-ATPase (Zheng and Ramirez, 1999). A synthetic oestrogen, diethylstilbestrol has also been
reported to inhibit rat liver FOF1-ATPase (McEnery and Pedersen 1986; McEnery et al. 1989).
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Flavones like quercetin, which are weak oestrogenic phytochemicals, have been reported to
inhibit bovine and porcine heart FOF1-ATPase (Lang and Racker 1974; Di Pietro et al. 1975).
Thymoquinone, a major phytochemical compound found in the black seeds of the medicinal
plant Nigella sativa, was shown to strongly inhibit ATPase activity and bacterial growth (Ahmad
et al. 2015). Piceatannol inhibits ATP synthase by targeting the F1 sector and exhibits mixed
inhibition of F1-ATPase activity (Zheng and Ramirez 1999). Resveratrol was found to show a
non-competitive inhibition of F1-ATP synthase activity (Zheng and Ramirez 2000).
3. Polyketide inhibitors that are polymers of two carbon ketide units synthesized by the
enzyme polyketide synthases. These types include natural macrolides like apoptolidin,
cytovaricin, oligomycin, peliomycin, ossamycin, and venturicidin.
Oligomycin is the inhibitor that led to the name 'FO’ for the intramembrane hydrophobic
region of ATP synthase. Oligomycin inhibits the apoptosis incited by Bax, a pro-apoptotic Bcl-2
family member protein found on the mitochondrial outer membrane, and ATP synthase activity
is needed for the killing of cells by Bax (Matsuyama et al. 1998). Oligomycin also activate
apoptosis in tumour cells (Wolvetang et al. 1994).
4. Organotin compounds and structural relatives: These are tin containing organic
compounds. They are grouped into R4Sn, R3SnX, R2SnX2, and RSnX3. Examples
include; tributyltin chloride, tricyclohexyltin hydroxide, triethyltin sulfate, triphenyltin
chloride and triethyllead, etc (Von Ballmoos et al. 2004).
5. Polyenic α-pyrone derivatives: α-Pyrone (a six membered cyclic unsaturated ester) and
its derivatives are known to inhibit ATP synthase. Derivatives include aurovertin,
citreoviridin and asteltoxin (Hong and Pedersen 2008).
6. Cationic inhibitors:
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•

Amphiphilic cationic dyes containing a basic amine group and a lipophilic
portion. They include rhodamine 123, acridine orange, rhodamine 6G, rosaniline,
rhodamine B, malachite green, quinacrine, pyronin Y, safranin O, nile blue A and
ethidium bromide (EtBr).

•

Tertiary amine local anesthetics (TALAs) which consist of an aromatic group, an
middle chain, and a terminal amine group. They include tetracaine, dibucaine,
procaine, lidocaine, chlorpromazine, trifluoperazine, trifluoperazine and
propranolol.

•

Other organic cations such as octyl guanidine, spermidine, atrazine, PDT-ferrous
chelate and DPBP-ferrous chelate (Hong and Pedersen 2008).

7. Substrates and substrate analogs that include phosphate analogs, divalent metal ions,
purine nucleotides and nucleotide analogs.
8. Amino acid modifiers that include amino group modifiers, carboxyl group modifiers,
cysteine and tyrosine residue modifiers and histidine residue modifiers
9. Miscellaneous inhibitors that include dicarbopolyborate, almitrine, n-butanol, 4,4΄dichlorodiphenyltrichloroethane (DDT) and 4,4΄-dichlorodiphenyltri- chloroethane
(DMSO) (Hong and Pedersen 2008).

Antimicrobial Peptides
Antimicrobial peptides are a unique and diverse group of active biological molecules that
are produced by different organisms as a valuable and crucial constituent of their innate immune
system. Most AMPs have similar features such as cationicity and amphipathicity. They are
generally comprised of 12 to 50 amino acids, but differ in several characteristics including their
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primary structure, the presence of disulphide bonds, and in a number of posttranslational changes
like amidation of C-terminal residues, pyroglutamation of N-terminal glutamine residues,
sulphation of tyrosine, hydroxylation of proline, and racemisation of certain L-amino acids to
their D-isomers (Bevins and Zasloff 1990; Erspamer 1994). Based on their secondary structure
AMPs follow four structural themes: α-helical peptides, β-stranded peptides, extended peptides
and β-hairpin or loop peptides (Dhople et al. 2006). Previous studies have demonstrated that they
often have wide spectrum activity against viruses, fungi, bacteria, protozoans, parasites and
cancerous cells.
The basic function of AMPs is host protection by making use of cytotoxicity to
pathogenic organisms. AMPs bind to negatively charged residues of microbial membranes where
peptide complexes form pores that break down the cell membrane or disturb metabolic processes
in the target. They also play immune modulators in more advanced organisms (Zanetti 2004). In
addition to their antimicrobial function, AMPs may be used as antitumor agents, contraceptive
agents, mitogenic agents, drug delivery vectors, and signaling molecules in signal transduction
pathways (Kamysz et al. 2003). Laughlin and Ahmad 2010 report the first candid experimental
proof of amphibian antimicrobial peptides as potential E. coli ATP synthase inhibitors testing
samples from both purified F1 - ATPase and membrane bound F1FO - ATP synthase. Currently,
there are more than 2700 entries into the Antimicrobial Peptide Database (APD)
(http://aps.unmc.edu/AP/main.php Wang et al. 2015), out of which 2255 (83.14%) are known to
have antibacterial property, 988 (36.43%) have antifungal property, 196 (7.22%) are anticancer
peptides, and 177 (6.52%) are identified as having antiviral activity. The diversity of
antimicrobial peptides apparently reflects adaptation to the particular microbial communities
associated with the environments of different species (Boman 2000).
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Linear cationic α-helical Peptides; Mastoparans and Lasioglossins
Linear cationic α-helical peptides are small peptides rich in hydrophobic and basic amino
acid residues. They are usually 10 to 45 amino acid residues long. They can adopt α-helical
amphipathic secondary structure in the cell membrane environment, or in the presence of such
membrane, and thereby have effects similar to substances such as trifluoroethanol (TFE) or
sodium dodecyl sulfate (SDS). They are often found in insects, and amphibian skin, as well as
arthropod venoms, and possess antimicrobial activity against a wide range of bacteria (Cerovsky
et al. 2008). Venoms are a highly evolved and rich source of natural cocktails of biochemically
active enzymes, proteins, peptides and other molecules, each of which plays a defined role
through interaction with highly specific molecular targets. Venom peptides have very strong and
selective effects, and may serve as potential drugs or scaffolds for drug design. Many venom
peptides are used in proof-of-concept studies in vivo, with many undergoing preclinical or
clinical development for use in the treatment of diabetes, epilepsy, multiple sclerosis,
cardiovascular disorders, pain, cancer and other neurological disorders. Captopril (Capoten;
Anakena) from the Brazilian arrowhead viper (Bothrops jaracusa), was the first model of a
successful venom-based drug. This drug inhibits angiotensin converting enzyme (ACE), a vital
enzyme in the production of angiotensin, which is in turn a vasoconstrictor affiliated with
hypertension (Cushmann and Ondetti 1991). Chlorotoxin, a peptide derived from the venom of
the desert scorpion Leiurus quinquestriatus, has been established as an effective treatment for
malignant glioma (Soroceanu et al. 1998). Exenatide, a synthetic analogue of exendin-4, the
venom peptide of the gila monster lizard Heloderma suspectum, is ready for use as a prescription
medicine in the treatment of Type 2 diabetes and related metabolic disorder (Nielsen et al. 2004).
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Mastoparans are the mast cell degranulating peptides from the venoms of vespid wasps
(Vespidae), has been identified as the dominant peptide found in the venoms of several species
of hornets (Nakajima 1984). They are tetradecapeptides characterized by 7 - 10 hydrophobic
amino acid residues and from 2 - 4 lysine residues in their basic sequence (Nakajima 1986).
Mastoparans also form the most abundant class of peptides in the venoms of social wasps (Hirai
et al. 1979). Their biological characteristics include the activation of enzymes like phospholipase
A2, phospholipase C, guanylate cyclase and G proteins (Higashijima et al. 1990; Dong-Li et al.
1993). Mastoparan is an effective stimulator of exocytosis in many mammalian cell types.
Mastoparan causes the secretion of histamine from mastocytes, catecholamines from
pheochromocytes, serotonin from thrombocytes, and prolactin from the adenohypophysis (Hirai
et al. 1979; Kuroda et al. 1980; Kurihara et al. 1986). When mastoparan interact with the
phospholipid bilayer it creates an α-helical structure that aligned to the surface of the membrane,
the hydrophobic region is inside the bilayer with its four positive charges (three Lys residues and
a terminal amino group) lining the exterior (Higashijima 1983; Wakamatsu et al. 1983).
Mastoparan B from the venom of the hornet species Vespa basalis has high mast cell
degranulation activity, a mastocytotropic peptide, with well-defined amino-acid sequence
different from the other vespid mastoparans. Explicit differences in amino acid sequence were
present at positions 1, 2, 5, 8 and 9, where mastoparan B has less hydrophobic amino acids like
Leul, Lys2, Ser5,8 and Trp9, rather than Ile1, Asn2, Ala5,8 and Leu9 or other amino acids as seen in
many other Vespa mastoparans (Hirai et al. 1979). When compared to the sequence of the
prototypic mastoparan (Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2)
(Hirai et al. 1979), mastoparan B may present a more hydrophilic surface, potentially causing
differences in its biological activity.
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Lasioglossins are members of a distinct group of AMPs that are found in the venom of
the wild eusocial bee Lasioglossum laticeps. These peptides exhibit strong antimicrobial activity,
low haemolytic activity, and cytotoxic activity against various cancer cells in vitro (Cerovsky et
al. 2008). Lasioglossins has a net charge of +6 fitting within the broad class of essential AMPs
with net charge varying from +4 to +6, which symbolize the maximum charge for antimicrobial
activity (Tossi et al. 2000). They exhibit low mast cell degranulation activity. The VNWK
sequence structure of lasioglossins is similar to the INWK sequence structure of a few
mastoparans obtained from other species of social wasps (Čeřovský et al. 2008).

Vespa basalis Mastoparan B sequence
H-Leu-Lys-Leu-Lys-Ser-Ile-Val-Ser-Trp-Ala-Lys-Lys-Val-Leu-NH2

Lasioglossum laticeps Lasioglossin II (LL-II) sequence
H-Val-Asn-Trp-Lys-Lys-Ile-Leu-Gly-Lys-Ile-Ile-Lys-Val-Ala-Lys-NH2
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Mastoparan B

Lasioglossin II (LL-II)

Figure 1. Helix-wheel plots of venom peptides sequence mastoparan B and lasioglossin II (LLII). The size of the downward arrow ↓ reflects the extent of hydrophobicity. Hydrophobic and
hydrophilic faces are shown in yellow and blue colors respectively. (http://heliquest.ipmc.cnrs.fr/
Gautier et al. 2008).

Potential Mechanism of Action of Antimicrobial Peptide
Antimicrobial peptides are thought to be structured such that they interact with a
biomembrane. The initial mechanism by which AMPs target pathogens occurs by means of an
electrostatic synergy between positive charged antimicrobial peptides and the negatively charged
lipid membranes of bacteria. In receptor-mediated membrane interactions, some antimicrobial
peptides expressly bind to bacterial lipid II, a negatively charged membrane bound constituent
tangled in peptidoglycan synthesis (Yeaman and Yount 2003).
After initial membrane binding, AMPs may go into a second phase of membrane
connection known as the threshold concentration. Peptides infiltrate and crisscross the lipid
18

bilayer by mean of several probable methods, amplifying their antimicrobial activity to focus on
the inner cell membrane. Theoretically, the threshold concentration needed to propel such
occurrence is caused by a build-up of peptides on the cell membrane. A number of factors
including tendency to self-associate or multimerization, peptide concentration, fluidity,
phospholipid membrane constitution, and head group size likely influence this threshold (Yang
et al. 2000). After membrane binding, another major event happening is the peptide structural or
conformational phase transformation. The peptides immediately adopt a well-structured
amphipathic α-helical conformation in membrane mimetic solvents, or upon interaction with
phospholipid bilayers. β-sheet antimicrobial peptides are consistently organized in membrane
environments and aqueous solution, because of constraints dictated by cyclization of the peptide
backbone or disulfide bonds. Self-assemble or multimerize of antimicrobial peptides may occur
following initial binding with the target cell membranes. Peptide-lipid and peptide-peptide
interactions inside membranes apparently form elaborate structures affiliated with individual
antimicrobial peptide mode of action (Yeaman and Yount 2003).
Membrane permeation by amphipathic α-helical or β-sheet peptides is thought to proceed
via one of the following mechanisms:
1. In the Barrel Stave Mechanism, the ‘stave’ caption alludes to individual transmembrane
rods within this barrel, which consist of single peptides or peptide complexes. Here,
varying amount of channel building peptides are placed in a barrel like loop about the
aqueous pores. The hydrophobic planes of α-helical or β-sheet peptide faces outside
towards the acyl chains of the membrane, while the hydrophilic planes make the pore
lining (Breukink and Kruijff 1999).
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2. In the Toroid Pore or Wormhole Mechanism, peptides in the outer cellular environment
assume the α-helical form as they correspond with the negatively charged hydrophobic
bacterial membrane. Lipids are inserted with peptides in the transmembrane channel,
forming a structure known as the supramolecular complex, which epitomize a membranespanning pore lined with the polar surfaces of peptides and the phospholipid head groups.
The hydrophobic residues of the connected peptides dislocate the polar head groups,
generating a gap in the hydrophobic plane and activating positive curvature strain in the
cell membrane (Hara et al. 2001a). The commencement of strain and thinning appears to
further destabilize the membranes surface quality making it also liable to change with
subsequent peptide connections. Some peptide may become displaced to the cytoplasmic
leaflet of the membrane upon fragmentation of the pore. Uematsu and Matsuzaki (2000)
suggest that toroid pore break down might be the major mechanism through which
peptides move into the microbial cytoplasm to affect possible intracellular destinations.
3. The Carpet Mechanism model, some peptides oppose microorganisms in a comparably
diffuse mode. This is a model of nonspecific membrane permeabilization by AMPs
which includes widespread results that have been compared to detergents. However,
peptides in this mechanism are not indiscriminate membrane detergents. Here, a high
mass of peptide aggregates on the target membrane surface (Yeaman and Yount 2003).
Phospholipid dislocation, decline in membrane barrier properties and/or alterations in
membrane fluidity may consequently leads to membrane disruption.
Peptides can develop membrane pores in microbe cells as explained earlier, this results in
the discharge of metabolites and ions, biopolymer synthesis and loss of membrane coupled
respiration, subsequent depolarization, and eventually cell death. However, evidence also
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supports complementary mechanisms including inhibition of intracellular processes and
inhibition of extracellular biopolymer synthesis as mechanisms involved in cell death
(Yeaman and Yount 2003).

History of ATP Synthase Research
A brief history of ATP synthase written by Boris A. Feniouk (2010) and published on
http://www.atpsynthase.info/History.html is summarized in the following. Karl Lohmann, a
biochemist at Kaiser Wilhelm Institute for Experimental Medicine in Heidelberg, Germany
discovered ATP from muscle and liver extract in 1929. A Russian biochemist Vladimir
Engelhardt in 1935 noted that ATP was part of a coenzyme complex associated with respiration
and is required for muscle contraction. ATP had been thought-out to be the final product of
catabolic reactions. In 1937, Herman Kalckar entrenched that ATP synthase is connected to cell
respiration. The caption oxidative phosphorylation was coined in 1939 by Belitser and
Tsibakova. From 1939 to 1941, Fritz Lipmann demonstrated that ATP is the principal carrier of
chemical energy in the cell. He also invented the catchphrase "energy rich phosphate
bonds". Slater developed a hypothesis involving chemical intermediates to clarify the
mechanism of oxidative phosphorylation in 1953. Coupled oxidative phosphorylation was
reported to be triggered by the soluble factor in the bacterial particulates in 1956. In 1960,
Penefsky and his group reported that soluble adenosine triphosphatase (ATPase) participated in
oxidative phosphorylation, it was isolated and termed factor 1 or F1 by Ephraim Racker in 1961.
In 1961, Robert J.P. Williams proposed that there are no energy rich intermediates however
protons help to transfer energy to ATP synthase from the photosynthetic proteins and respiration
chain enzymes. Also in 1961, Peter Mitchell reported his chemiosmotic hypothesis, affirming the
21

basic function of membranes that divide the two sections, and suggesting that the membrane
proteins provide a gradient of protons created by the respiration chain enzymes, which are then
used by ATP synthase but not by the chemical intermediates. In 1964, Paul D. Boyer suggested
that ATP molecule is synthesized owing to structural adjustments in the ATP synthase enzyme
and in 1973 Boyer’s group proposed that during ATP synthesis the phase which needs energy, is
the releasing of ATP from the enzyme. Boyer and his group conceptualized the binding change
mechanism that describes changes in the catalytic subunit of the F1FO during ATP synthesis and
hydrolysis. The DNA sequence of genes encoding the proteins in ATP synthase was concluded
by John E. Walker's lab. The initial X-ray crystallography configuration of the F1 subunit
(without epsilon, delta, and part of the gamma subunits) analyzing individual amino acid
residues was completed by Walker and his group in 1994. In 1997, Kinosita and his group
reported direct observance of the rotation of F1 during hydrolysis of ATP. The Nobel Prize in
chemistry in 1997 was awarded to Paul D. Boyer and John E. Walker for their illustration of the
enzymatic mechanism fundamental to the synthesis of ATP and also to Jens C. Skou for first
discovering ion transporting enzymes, Na+, K+ ATPase. In 2004, the initial demonstration of an
endergonic chemical reaction being propelled by the direct precise input of mechanical energy
was accomplished by H. Itoh and his group.

Structure and Function of ATP Synthase
ATP synthase is an F-Type ATPase. ATPases are membrane-bound enzymes capable of
coupling ion movement through a membrane with the hydrolysis or synthesis of ATP. Based on
structural and functional differences, ATPases can be grouped into F-, V-, E-, P- and AATPases. All these ATPases catalyze ATP synthesis or hydrolysis. The F-ATPases for
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‘phosphorylation Factor’ are also referred to as H+-transporting ATPases or F1FO-ATPases. FATPases provide a kind of transporter for H+ ions to move through the membrane and possess a
unique rotary motor-like mechanism that is coupled with the flow of ions. ATP synthase from
diverse taxa have amino acid sequence similarity and appear to be remarkably conserved
throughout evolution. F1FO-ATP synthase is also structurally and functionally similar among
different organisms. The simplest form, and the most used model, is the Escherichia coli ATP
synthase. The enzyme has a total molecular mass of approximately 530 kDa. E. coli ATP
synthases have two functional rotary sectors: the intramembrane hydrophobic region called
FO sector, and the catalytic hydrophilic F1 sector (Figure 2) (Boyer 1997).
The FO sector consist of three subunits a, b and c, in the stoichiometry of ab2c10-14 with
masses of about 30, 17 and 8 kDa respectively. The F1 sector has five subunits, α, β, γ, δ, and ε,
in the stoichiometry of α3β3γδε with masses of about 55, 50, 31, 19 and 14 kDa respectively
(Boyer 1997; Ackerman and Tzagoloff 2005). ATP synthesis and hydrolysis occur in the F1
region, whereas proton pumping occurs through the intramembrane hydrophobic FO region
(Senior et al. 2002, Abrahams et al. 1994). There are six possible substrate binding sites on the
F1 sector. The binding sites on the three β-subunits are active catalytic sites, but those on the
three α-subunits are noncatalytic regulatory sites. ATP synthase has two rotational motors, one in
the F1 (γ and ε subunits) driven by ATP hydrolysis, the other in FO (c subunit) driven by the
H+ gradient, which are joined together so that the two motors undergo rapid continuous 360º
rotation as catalysis proceeds (Noji et al. 1997). The two motors are physically connected by two
stalks. The γ subunit consists of three α-helices, two of which form a coiled coil configuration
that insert into the central stalk of the α3β3 hexagon. The δ and b subunits form the peripheral
stalk. Proton gradient driven clockwise rotation of γ leads to ATP hydrolysis, and anticlockwise
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rotation of γ results in ATP synthesis. Under mild dissociation conditions the F1FO-ATP synthase
dissociates into the F1 and FO sectors which can be isolated and studied individually. In
summary, the rotor consists of γεcn, while the stator consists of α3β3δab2, and the function of the
stator is to prevent co-rotation of catalytic sites with the rotor (Itoh et al. 2004; Weber 2006).
ATP synthase structure and function detailed studies can be found in (Noji and Yoshida 2001;
Weber and Senior 2003; Ahmad and Senior 2005; Pedersen 2007; Senior 2007).

Figure 2. Structure of F1FO ATP synthase. F1 sector contains five types of subunit with a
stoichiometry α3β3γδε and FO contains three types of transmembrane subunits with a
stoichiometry a1b2c10–14. (Reproduced with permission from Yoshida et al. 2001).

24

Figure 3. Cartoon representation of the structure of the isolated E. coli γε complex with
the ε-subunit in the partially extended confirmation. A pair of α and β subunits are displayed in
light-grey, subunit γ is dark-grey, subunit ε is displayed in the van der Waals representation (red
is the discreet region of the β sandwich, blue is the region preserved only between bacterial and
chloroplasts enzyme and the rest is white), βDELSEED-loop is displayed in yellow. (Reproduced
with permission from Feniouk et al. 2006).
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CHAPTER 2
MATERIALS AND METHODS
Source of Peptides and Other Chemicals
Mastoparan B and lasioglossin II were custom synthesized by Biomatik Corporation.
Both peptides were received as lyophilized powder shipped on dry ice and their HPLC
determined purity was greater than 97%. Once received, they were stored at -20ºC and
subsequently resuspended in autoclaved deionized water when needed. Other chemicals used in
this study were ordered from Fisher Scientific, Sigma-Aldrich, and Acros organics.

Preparation of E. coli Membrane Associate F1FO ATP Synthase
Membrane bound F1FO was isolated from the E. coli strain pBWU13.4/DK8 (Ketchum et
al. 1998). E. coli membrane bound F1FO was prepared as follows (Senior et al. 1983). Minimal
medium was inoculated with a loop full of E. coli strain pBWU 13.4/DK8 and was aerobically
cultivated over night at 37°C at 250 rpm. The overnight starter culture was inoculated into 1 liter
minimal medium and grown at 37°C at 250 rpm. Growth yield was measured at OD595 (optical
density) every hour until late log phase was reached. Once the required growth was observed the
cells were harvested. Cells were maintained as close to 0°C as possible for subsequent steps.
Cells were harvested by spinning the culture at 4°C in a Sorvall RC-5B refrigerated super speed
centrifuge at 9500 rpm for 15 min. The cells were then resuspended in STEM buffer containing
20mM sucrose and centrifuged at 9500 rpm for 25 min. The supernatant was discarded and the
cell pellet was resuspended in 2 ml STEM/g wet cells and stored at -80°C overnight.
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The frozen cells were thawed and mixed with DNAse to digest nucleic acids. Cells were then
disrupted by two passages through a chilled French press cell fractionator at 20,000 psi. Cell
debris were pelleted by centrifugation at 18K rpm for 20 min using Sorvall WX ultra-80, ultracentrifuge. Membrane bound ATP synthase was subsequently pelleted by spinning the
supernatant at 60K rpm for 120 min.
E. coli membranes were purified following a procedure consisting of three washes of the
initial membrane pellets (Senior et al. 1984). The initial wash was performed in a buffer
containing 50mM TES pH 7.0, 15% glycerol, 40mM 6-aminohexanoic acid, and 5mM paminobenzamidine. Two subsequent washes were performed in a buffer containing 5mM TES
pH 7.0, 15% glycerol, 40mM 6-aminohexanoic acid, 5mM p-aminobenzamidine, 0.5mM DTT
and 0.5mM EDTA. The final membrane bound F1FO ATP synthase was resuspended and stored
in 50 mM TrisSO4 pH 8.0, 2.5 mM MgSO4 at -80°C (Noji and Yoshida 2001).

Measurement of Membrane Associated F1FO ATP Synthase Activity
ATPase activity was measured in a 1ml assay buffer containing 10mM NaATP, 4mM
MgCl2, and 50mM TrisSO4, at pH 8.5 and 37ºC. Reactions were initiated by the addition of 1ml
of assay buffer to 20 µg of membrane associated F1FO ATP synthase and then terminated by
adding SDS to 3.3% ﬁnal concentration. Inorganic phosphate (Pi) release was assayed by adding
1ml of Taussky and Shorr (T&S) reagent containing 10 mM (NH4)6Mo7O24·4H2O, 250 mM
Fe(NH4)2(SO4)2·6H2O, and 1.176N H2SO4. T&S reacts with Pi to form a blue color complex.
The intensity of the blue color was measured at OD700 using Shimadzu UV-visible recording
spectrophotometer (Taussky and Shorr 1953). Here, ATPase activity was measured in terms of
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ATP hydrolysis rather than the synthase activity. ATPase hydrolytic activity was measured to
test ATP synthase functionality. The hydrolysis rate is correlated to the enzyme activity, and also
provides useful information on possible inhibitory effects of compounds that hinder the
hydrolytic process.
The reaction is as follows:
ATP + ATP synthase ⇌ ADP + Pi
Pi + T&S → blue color measured at OD700

ATPase activity in µmol/min/mg was calculated using the formula:
̳ Average Sample OD - Average Blank OD
Amount of protein (mg) x Time (min)

Inhibition of ATPase activity by Mastoparan B and Lasioglossin II
Membrane bound F1FO ATP synthase was preincubated with varied concentrations of
mastoparan B and lasioglossin II for 60 min at room temperature in 50 mM TrisSO4 pH 8.0.
Then 1 ml ATPase assay buffer containing 10 mM NaATP, 4 mM MgCl2, 50 mM TrisSO4, and
pH 8.5 was added and kept at 37ºC for 15 min to measure enzyme activity. The reaction was
terminated by the addition of SDS to a final concentration of 3.3%. Pi release was assayed by
adding 1ml of T&S reagent. The intensity of the blue color was assayed spectrophotometrically
at OD700 using Shimadzu UV-visible recording spectrophotometer (Taussky and Shorr 1953).
Data analysis was performed using Minitab software (Minitab 2014).
% relative activity was calculated using the formula;
Specific activity of the test inhibitor
Specific activity of the blank
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CHAPTER 3
RESULTS
Inhibitory Effect of Lasioglossin II on Membrane Bound E. coli ATP Synthase
Inhibition of membrane bound E. coli ATP synthase was tested by measuring the mean
relative ATPase activity (Figure 4) of membrane bound F1FO that had been preincubated with
varied concentrations of lasioglossin II (10µM - 400µM) for 60 min at room temperature. The
estimated mean was obtained from three independent inhibition experiments (Appendix D). The
results show lasioglossin II as a very weak inhibitor (Figure 4). The maximum estimated amount
of inhibition by lasioglossin II was ~ 18% with ~ 82% residual activity at a concentration of
400µM. The least amount of inhibition was at a concentration of 10µM, with ~ 2% inhibition and
~ 98% residual activity. A one-way ANOVA indicates statistically significant differences among
the various concentrations of lasioglossin II tested (P<0.000) (Table 1). Multiple comparisons by
Fisher’s least significant difference method indicates significant differences in the extent of
inhibition between higher and lower concentrations of peptide (Table 2).

Table 1. One – way ANOVA table for ATPase activity of membrane bound E. coli ATP synthase
in the presence of varied concentrations of lasioglossin II

Source
Factor
Error
Total
Standard Deviation
R-square %
Adjusted R-square %
Predicted R-square %

Analysis of Variance
Degrees of Adjusted Sums Adjusted
F-Value
Freedom
of Squares
Mean Squares
5
492.35
98.471
96.55
12
12.24
1.020
17
504.59
1.00990
97.57
96.56
94.54
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P-Value
0.000

Inte rval Plot of varie d conce ntration of Las ioglos sin II (µM)
95% CI for the Mean

Mean Relative ATPase Activity (%)
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Individual standard deviations were used to calculate the intervals.

Figure 4. Inhibition of ATPase activity of membrane bound E. coli ATP synthase in the presence
of varied concentrations of lasioglossin II

Table 2. Inhibition of ATPase activity of Escherichia coli ATP synthase enzyme and residual

Lasioglossin II

% Mean Relative

Standard

Concentration (µM)

ATPase Activity

Deviation

Interval

10

98.10

0.59

96.63 - 99.56

20

97.89

0.95

95.52 - 100.25 A

40

96.45

0.97

94.04

- 98.86

80

93.12

1.33

89.80

- 96.43

B

100

93.06

1.44

89.47

- 96.65

B

400

82.79

0.23

82.22

- 83.36

Means that do not share a letter are significantly different.
ATPase activity in the presence of lasioglossin II

30

95% Confidence Fisher Pairwise
Comparisons
A

A

C

Inhibitory Effect of Mastoparan B on Membrane Bound E. coli ATP Synthase
Concentrations of mastoparan B ranged from 50 to 1000µM, with the estimated degree of
inhibition varying from 0 to 55% (Figure 5). Membrane bound F1FO (6.1µl) was preincubated
with varied concentrations of mastoparan B (50µM - 1000µM) for 60 min at room temperature,
then

1 ml of ATPase assay buffer was added to measure enzyme activity. The estimated

mean was obtained from three independent inhibition experiments (Appendix D). The maximum
amount of inhibition estimated in the presence of mastoparan B was ~ 55%, with ~ 45 % residual
activity at a concentration of 800µM (Figure 5). The least amount of inhibition estimated in the
presence of mastoparan B tested was at a concentration of 50µM and was ~ 10% with ~ 90%
residual activity (Figure 5). Estimates of the concentration dependent inhibition are suggestive
of a partial inhibitory effect but only at very high concentrations. A one-way ANOVA indicates
statistically significant (P < 0.003), differences among the various peptide concentrations used
(Table 3). Multiple comparisons by Fisher’s least significant difference method indicate
significantly greater inhibition by 250µM, and higher concentrations of peptide and significantly
lower inhibition at 50µM (Table 2).

Table 3. One – way ANOVA table for ATPase activity of membrane bound E. coli ATP synthase
in the presence of varied concentrations of mastoparan B
Source
Factor
Error
Total
Standard Deviation
R-square %
Adjusted R-square %
Predicted R-square %

Degrees of
Freedom
8
18
26
13.4091
67.50
53.05
26.87

Adjusted Sums
of Squares
6721
3236
9957
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Adjusted
F-Value
Mean Squares
840.1
4.67
179.8

P-Value
0.003

Interval Plot of varied concentration of Mastoparan B (µM)
95% CI for the Mean

M e an R e lative A TPas e A ctivity (% )

160
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100
80
60
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0
50

100
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800

1000

Individual standard deviations were used to calculate the intervals.

Figure 5. Inhibition of ATPase activity of membrane bound E. coli ATP synthase in the presence
of varied concentrations of mastoparan B.

32

Table 4. Inhibition of ATPase activity of Escherichia coli ATP synthase enzyme and residual

Mastoparan B

Mean % Relative Standard 95% Confidence

Fisher Pairwise

Concentration (µM)

ATPase Activity

Deviation

Interval

50

90.60

23.30

32.79 - 148.41 A

100

75.17

15.33

37.09

- 113.24 A

B

150

76.73

14.51

40.68 - 112.78 A

B

200

75.10

13.16

42.42 - 107.78 A

B

250

51.13

7.42

32.70 - 69.57

C

300

48.30

4.95

36.00 - 60.60

C

400

54.03

12.29

23.51 - 84.56

800

44.97

7.28

26.87 - 63.06

C

1000

47.70

13.21

14.88 - 80.52

C

Means that do not share a letter are significantly different.
ATPase activity in the presence mastoparan B

33

Comparisons

B

C

CHAPTER 4
DISCUSSION

In this study the inhibitory effect on Escherichia coli ATPase activity by the two venom
peptides lasioglossin II and mastoparan B was examined. The estimation of mean inhibitory
effects using ANOVA reveals that varied concentrations of both lasioglossin II and mastoparan
B were statistically significant. Varied lasioglossin II concentrations from 10µM to 100µM
caused very low inhibition of ATPase activity (Figure 4). At a concentration of 10µM, ~ 2%
inhibition was observed, and only ~ 7% inhibition was seen at the concentration of 100µM. The
maximal inhibition induced by lasioglossin II was ∼18% at a concentration of 400µM. The
mastoparan B inhibition profile was suggestive of an interesting biological effect with maximal
inhibition of ∼55% at a concentration of 800µM. Partial inhibition of ATP synthase by other
potential inhibitors has been reported previously. Dadi et al. (2009) reported that the maximal
inhibition by luteolin was ~20%, daidzein was ~10%, and galangin showed no inhibition of
Escherichia coli ATPase activity. Previous studies have also shown that a variety of linear
cationic α-helical AMPs inhibit ATP synthase to varying degrees. Laughlin and Ahmad 2010
reported that amphibian AMPs aurein 2.2, aurein 2.3, carein 1.9, magainin II, and magainin IIamide gave partial inhibitory effects of ∼69%, 30%, 52%, 20% and 60% respectively at very low
molar concentrations, while carein 1.8 did not inhibit at all (0%). The honey bee venom peptides
melittin and melittin-amide inhibited ∼77% and ∼95% of enzyme activity respectively, while
melittin related peptide (MRP) and MRP-amide inhibited at ∼79% and ∼96% respectively.
The results obtained from this study also contrasts with results obtained on the inhibition
of ATP synthase by other venom peptides. Azim et al. (2016) documented the inhibitory effect
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of four venom peptides on Escherichia coli ATP synthase also at much lower concentrations
than the concentrations used in this study. King cobra OH-CATH (KF-34), wolf spider lycotoxin
II (KE-27), banded krait cathelicidin (BF-30), and wolf spider lycotoxin I (IL-25) induced very
strong inhibition of ATP synthase, as the maximum inhibition caused by KF-34, KE-27, BF-30
and IL-25 was ∼90%, ∼85%, ∼85% and ∼88% respectively.
The partial or slight inhibition obtained in this study might be the result of various
factors, inclusive of the sequence length of the peptides, cationicity, and amphipathic character.
The sequence length of the venom peptides OH-CATH (KF-34), cathelicidin (BF-30), lycotoxin
II (KE-27) and lycotoxin I (IL-25) are 34, 30, 27 and 25 amino-acids respectively, while
lasioglossin II and mastoparan B have lengths of 15 and 14 amino acids. In antibacterial studies
of two derivatives of esculentin-1 peptides, Esc-1a (1-21) NH2 was two to eight fold more active
against the planktonic form and exhibited a stronger anti-biofilm activity, inducing a 3 log
decrease in the amount of viable biofilm cells than Esc-1b (1-18) NH2 in many distinct strains of
the bacteria Pseudomonas aeruginosa. This difference was attributed to the longer length and
higher cationicity of Esc-1a (1-21) NH2 (Mangoni et al. 2015). Two additional factors play vital
responsibility in the action mechanism of AMPs, a net positive charge at neutral pH, because
cationicity depicts essential character that supports the interaction and binding of AMPs to the
negatively charged constituents of the microbial cell membrane, and amphipathic character
because this parameter affects the integration of specific peptide into the hydrophobic core of the
membrane lipid bilayers (Rietschel et al. 1994; Teixeira et al. 2012). The net positive charge and
the hydrophobic face of OH-CATH (KF-34), cathelicidin (BF-30), lycotoxin I (IL-25) and
lycotoxin II (KE-27) are also greater than that of lasioglossin II and mastoparan B.
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Cytolytic peptides with high antimicrobial activity such as lasioglossins and mastoparans
obtained from the venom of stinging insects have some characteristics that suggested them as
candidates for the development of effective antibiotic peptides based on their potential for antiATP synthase activity. In this study, statistically significant differences in ATP synthase activity
were observed in experiments with lasioglossin II, but the effects appear to have very limited
biological relevance. The results of inhibition experiments with mastoparan B were statistically
significant and were suggestive of some biologically relevant effects on ATP synthase.
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APPENDICES
APPENDIX A- Abbreviations
AMP- Antimicrobial Peptide
ATP- Adenosine triphosphate
ADP- Adenosine diphosphate
Leu [L] - Leucine
Lys [K] - Lysine
Ser [S] - Serine
Ile [I] - Isoleucine
Val [V] - Valine
Arg [R] - Arginine
Trp [W] - Tryptophan
Ala [A] - Alanine
Asn [N] - Asparagine
Gly [G] - Glycine
NBD-Cl- 4-chloro-7-nitrobenzofurazan
PAB- 4-aminobenzamidine
Pi - Inorganic phosphate
SDS- Sodium dodecyl sulphate
T&S- Taussky and Shorr
O.D- Optical density
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APPENDIX B: Buffers and Reagents
50 mM Tris-SO4 buffer
To 90 ml H2O add
0.61 g Tris
Adjust pH to 8.0 with H2SO4
Bring to a final volume of 100 ml with H2O

ATPase cocktail
In 150 ml H2O add
10 ml 1 M Tris
0.8 ml 1M MgCl2
5 ml 0.4 Na ATP (Adenosine 5̍-triphosphate disodium salt)
Adjust pH to 8.5 with H2SO4
Bring to a final volume of 200 ml with H2O
Freeze in plastic bottles at -20oC
10 % SDS
100 gm Sodium dodecyl sulfate
Bring to a final volume of 1000 ml with H2O
Taussky and Shorr reagent (T & S reagent)
Sol A: 1.2 g Ammonium molybdate ((NH4)6Mo7O24·4H2O in 9.8 ml 12 N H2SO4)
Sol B: 10 g Ferrous ammonium sulfate (Fe(NH4)2(SO4)2·6H2O in 70 ml H2O)
Add sol A to sol B while stirring
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Bring to a final volume of 100 ml with H2O
Store at 4oC
STEM
To 700 ml H2O add
100 ml 1 M TES
4.29 g Mg(CH3CO2)2·4H2O
85.5 g sucrose
0.0951 g EGTA (Ethylene glycol-bis(2-aminoethylether)-N,N,N,N-tetraacetic acid)
5 g EACA (6-Ainocaproic acid6-Ainocaproic acid)
Adjust pH to 6.5 with NaOH
Bring to a final volume of 1000 ml with H2O
Freeze in plastic bottles at -20oC
TES 50
To 700 ml H2O add
50 ml 1 M TES
150 ml glycerol
5 g EACA (6-Ainocaproic acid6-Ainocaproic acid)
1 g PAB (4-Aminobenzamidine dihydrochloride)
Adjust pH to6.5 with NaOH
Bring to a final volume of 1000 ml with H2O
Freeze in plastic bottles at -20oC
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TES 5 + PAB
To 700 ml H2O add
5 ml 1 M TES
150 ml glycerol
1 ml 0.5 M DTT (Dithiothreitol)
5 g EACA (6-Ainocaproic acid6-Ainocaproic acid)
1 g PAB (4-Aminobenzamidine dihydrochloride)
2.5 ml 0.2 M EDTA (Ethylenediaminetetraacetic acid disodium salt dihydrate)
Adjust pH to 6.5 with NaOH
Freeze in plastic bottles at -20oC

AET (Argenine Ent Thimine)
To 60 ml H2O add
0.617 g 2,3 Dihydroxy Benzoic acid
16.86 g L-Arginine HcL
1 ml 20 mM Thiamine
Add just enough amount of NaOH to dissolve everything
Make final volume to 100 ml with H2O
Filter sterile
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TE (Trace Elements)
To 80 ml H2O
0.251 g Zinc Sulfate (ZnSO4.7H2O)
0.017 g Manganese Sulfate (MnSO4.H2O)
0.029 g Boric acid (H3BO3)
0.012 g Calcium Sulfate (CaSO4.2H2O)
0.037 g Calcium Chloride (CaCl2.2H2O)
0.049 g Ferric Chloride (FeCl3.6H2O)
Make final volume to 100 ml with H2O
Filter sterile

ILV (Isoleucin-Valine)
To 95 ml H2O add
0.394 g Isoleucine
0.352 g Valine
Make final volume to 100 ml with H2O
Filter sterile
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APPENDIX C: Culture Media and Plates
LB liquid medium

12.5 g of LB broth powder
Add H2O to bring to 500 ml
Autoclave for 30 minutes
Cool the media to ~50oC
Add 500 µl of 100 mg/ml Ampicillin
Minimal Glucose

To 400 ml H2O add
5.225 g Potassium Phosphate Dibasic Trihydrate (K2HPO4)
2.40 g Sodium Phosphate Monobasic (NaH2PO4)
0.99 g Ammonium Sulfate ((NH4)2SO4)
Autoclave for 30 min, cool it and add the following additions
10 ml Uracil
10 ml 27 % Glucose
5 ml ILV (isoleucin-valine)
0.5 ml TE (trace elements)
0.5 ml 1 M Magnesium Sulfate (MgSO4)
0.5 ml AET (Argenine Ent Thimine)
0.5 ml 100 mg/ml Ampicillin
0.312 ml 4X LB
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LB-Agar plate with Ampicillin
12.5g of LB broth powder
7.5g of agar
Bring to a final volume of 500 mL
Autoclave for 30 minutes
Cool the media to ~50oC
Add 500 µl of 100 mg/ml Ampicillin
Pour into sterile plates
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APPENDIX D: Raw data
Result of three independent experiment

Lasioglossin II
Conc. (µM)
10
20
40
80
100
400

A

B

C

98.36
96.79
97.57
93.51
93.43
82.79

98.51
98.51
95.93
94.21
91.47
82.56

97.42
98.36
95.85
91.63
94.29
83.02

Mastoparan B
Conc. (µM)
50

A

B

C

107.7

64.1

100

69.6

150

% Mean Relative
ATPase Activity
98.10
97.89
96.45
93.12
93.06
82.79

Standard
Deviation
0.59
0.95
0.97
1.33
1.44
0.23

100

% Mean Relative
ATPase Activity
90.60

Standard
Deviation
23.27

92.5

63.4

75.17

15.33

61.9

77.4

90.9

76.73

14.51

200

60

81.2

84.1

75.10

13.16

250

49.6

44.6

59.2

51.13

7.42

300

52.4

49.7

42.8

48.30

4.95

400

67.7

43.9

50.5

54.03

12.29

800

52.8

38.4

43.7

44.97

7.28

1000

34.8

61.2

47.1

47.70

13.21
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